Time | Screening period | Baseline stage | Period of drug treatment(90d) | Follow-up | |||
---|---|---|---|---|---|---|---|
− 72 h | D0 | D14 ± 3 days | D28 ± 3 days | D60 ± 3 days | D90 ± 3 days | D180 ± 7 days | |
Visit date | X | X | X | X | X | X | X |
Inclusion/exclusion criteria | X | ||||||
Informed consent | X | ||||||
Demographic data | X | ||||||
Vital signs and physical examination | X | X | X | X | X | X | |
History of malignant tumor and aneurysm | X | ||||||
Family history, medical history and treatment history of TIA, Stroke, hemorrhagic disease | X | ||||||
Previous history of disease | X | ||||||
Allergic history | X | ||||||
History of tobacco and alcohol | X | ||||||
Routine blood | |||||||
RBC | X | X | |||||
WBC | X | X | |||||
Neutrophil | X | X | |||||
Lymphocyte | X | X | |||||
PLT | X | X | |||||
Hb | X | X | |||||
PCV | X | X | |||||
Urinalysis | |||||||
U-LEU | X | X | X | X | X | ||
U-BLD | X | X | X | X | X | ||
R-PRO | X | X | X | X | X | ||
U-Ket | X | X | X | X | X | ||
Routine stool | |||||||
OB | X | X | |||||
Liver function and kidney function | |||||||
ALT | X | X | X | X | X | ||
AST | X | X | X | X | X | ||
TBil | X | X | X | X | X | ||
BUN | X | X | X | X | X | ||
Scr | X | X | X | X | X | ||
Fasting lipid panel | |||||||
TC | X | X | |||||
TG | X | X | |||||
HDL | X | X | |||||
LDL | X | X | |||||
Fasting blood glucose | X | X | |||||
Coagulation function | |||||||
PT | X | X | X | X | X | ||
APTT | X | X | X | X | X | ||
FIB | X | X | X | X | X | ||
hs-CRP | X | X | |||||
Homocysteine | X | ||||||
ECG | X | X | |||||
MRI of brain | X | X | |||||
ADL scale (BI) | X | X | X | ||||
NIHSS | X | X | X | X | X | ||
mRS before stroke | X | ||||||
mRS | X | X | X | X | X | X | |
Recurrence rate | X | X | X | X | X | ||
Cardiovascular and cerebrovascular events | X | X | X | X | X | ||
Bleeding event | X | X | X | X | |||
Mortality rate | X | X | X | X | X | ||
AE and SAE | X | X | X | X | X | ||
Combined use of drugs | X | X | X | X | X | ||
Adherence evaluation | X | X | X | X |